AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21212378 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal speed during treadmill test
Number of subjects: 23
Study 21212378 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walking distance
Number of subjects: 23
Study 21212378 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate response, oxygen pulse, and OUES
Number of subjects: 23
Study 17611132 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (40 mg orally the evening before and 40 mg the morning of assessment)
Number of subjects: 12
Study 17611132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16829089 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump surgery
Number of subjects: 120
Study 16829089 — intervention group
Group type: COMPARATOR
Intervention: Off-pump surgery
Number of subjects: 120
Study 12883229 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) 1800 mg/d
Number of subjects: 63
Study 12883229 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) 1000 mg/d
Number of subjects: 63
Study 10969365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre MB (morphine and bupivacaine)
Number of subjects: 80
Study 10969365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre M (morphine)
Number of subjects: 80
Study 10969365 — intervention group
Group type: COMPARATOR
Intervention: Post MB (morphine and bupivacaine)
Number of subjects: 80
Study 8651747 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral placement of an endograft
Number of subjects: 17
Study 8651747 — intervention group
Group type: COMPARATOR
Intervention: Open endoaneurysmorrhaphy
Number of subjects: 17
Study 1451724 — intervention group
Group type: EXPERIMENTAL
Intervention: O-(beta-hydroxyethyl)-rutosides (HR) 2 x 1.5 g IV before surgery
Number of subjects: 8
Study 1451724 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 8
Study 6396153 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oral co-trimoxazole
Number of subjects: 67
Study 6396153 — intervention group
Group type: COMPARATOR
Intervention: Five-day oral co-trimoxazole
Number of subjects: 67
Study 30807389 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling followed by PMMA-collagen gel filler
Number of subjects: 44
Study 30807389 — intervention group
Group type: COMPARATOR
Intervention: Microneedling alone
Number of subjects: 44
Study 29994882 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure target of 72 mm Hg
Number of subjects: 100
Study 29994882 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure target of 77 mm Hg
Number of subjects: 100
Study 26197302 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 30
Study 26197302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26197302 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 30
Study 24386744 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast/bottle feeding
Number of subjects: 192
Study 24386744 — intervention group
Group type: COMPARATOR
Intervention: Spoon/syringe feeding
Number of subjects: 192
Study 21318926 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective message
Number of subjects: 580
Study 21318926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive message
Number of subjects: 580
Study 21318926 — intervention group
Group type: COMPARATOR
Intervention: No-message control
Number of subjects: 580
Study 19175510 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-plus-exercise interventions
Number of subjects: 18
Study 19175510 — intervention group
Group type: COMPARATOR
Intervention: Diet-only interventions
Number of subjects: 18
Study 17098529 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity vein bypass for CLI
Number of subjects: 1404
Study 14751942 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 rev/min during lower body exercise (LE)
Number of subjects: 24
Study 14751942 — intervention group
Group type: COMPARATOR
Intervention: 40 rev/min during lower body exercise (LE)
Number of subjects: 24
Study 14751942 — intervention group
Group type: COMPARATOR
Intervention: 40 rev/min during upper body exercise (UE)
Number of subjects: 24
Study 14751942 — intervention group
Group type: COMPARATOR
Intervention: 60 rev/min during lower body exercise (LE)
Number of subjects: 24
Study 14751942 — intervention group
Group type: COMPARATOR
Intervention: 60 rev/min during upper body exercise (UE)
Number of subjects: 24
Study 11347286 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador
Number of subjects: 10226
Study 11347286 — intervention group
Group type: COMPARATOR
Intervention: Control (no Iscador or mistletoe product)
Number of subjects: 10226
Study 11347286 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador with good self-regulation
Number of subjects: 10226
Study 11347286 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador with poor self-regulation
Number of subjects: 10226
Study 8435171 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative steroid treatment (methylprednisolone)
Number of subjects: 0
Study 8435171 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative steroid treatment (methylprednisolone)
Number of subjects: 0
Study 8435171 — intervention group
Group type: COMPARATOR
Intervention: SK&F 86002 (nonsteroidal dual cyclooxygenase/lipooxygenase inhibitor)
Number of subjects: 0
Study 8435171 — intervention group
Group type: COMPARATOR
Intervention: Delayed steroid administration
Number of subjects: 0
Study 8435171 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative steroid therapy (in double-blinded placebo-controlled study)
Number of subjects: 0
Study 8435171 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study 3304117 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (360 mg/24 h)
Number of subjects: 0
Study 3304117 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/24 h)
Number of subjects: 0
Study 30575794 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis extract (PPE) entrapped in niosomes
Number of subjects: 24
Study 30575794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 27062960 — intervention group
Group type: EXPERIMENTAL
Intervention: YOGA
Number of subjects: 26
Study 27062960 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 26
Study 26181217 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid response teams (intervention)
Number of subjects: 3135
Study 26181217 — intervention group
Group type: COMPARATOR
Intervention: Delayed calls
Number of subjects: 3135
Study 24013685 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline UPCR < 1.0 g/gCr
Number of subjects: 566
Study 24013685 — intervention group
Group type: COMPARATOR
Intervention: Worsening UPCR (<0%) at 24 weeks
Number of subjects: 566
Study 24013685 — intervention group
Group type: COMPARATOR
Intervention: Remission at 24 weeks
Number of subjects: 566
Study 24013685 — intervention group
Group type: COMPARATOR
Intervention: Residual UPCR ≥ 1.0 g/gCr and ΔUPCR <30%
Number of subjects: 566
Study 20805623 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose unfractionated heparin, 50 U/kg
Number of subjects: 2026
Study 20805623 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose unfractionated heparin, 85 U/kg (60 U/kg with GpIIb‐IIIa inhibitors)
Number of subjects: 2026
Study 18180682 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3%
Number of subjects: 110
Study 18180682 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5%
Number of subjects: 110
Study 18180682 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% and Moxifloxacin 0.5%
Number of subjects: 110
Study 16760927 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone augmentation (0.25-2.0 mg/day)
Number of subjects: 489
Study 16760927 — intervention group
Group type: COMPARATOR
Intervention: Placebo augmentation
Number of subjects: 489
Study 16760927 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone augmentation (0.25-2.0 mg/day) in fully nonresponsive patients
Number of subjects: 489
Study 16760927 — intervention group
Group type: COMPARATOR
Intervention: Placebo augmentation in fully nonresponsive patients
Number of subjects: 489
Study 12831271 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitor-mounted copy strip
Number of subjects: 110
Study 12831271 — intervention group
Group type: EXPERIMENTAL
Intervention: Copy strips and labeled product sleeves on stock bottles
Number of subjects: 110
Study 12831271 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 110
Study 10657266 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 72
Study 9663833 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ABT-229
Number of subjects: 9
Study 9663833 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg ABT-229
Number of subjects: 9
Study 9663833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8093495 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-strength milk feeding
Number of subjects: 159
Study 8093495 — intervention group
Group type: COMPARATOR
Intervention: Diluted milk feeding
Number of subjects: 159
Study 3527181 — intervention group
Group type: EXPERIMENTAL
Intervention: suprofen syrup 10 mg/ml
Number of subjects: 60
Study 3527181 — intervention group
Group type: COMPARATOR
Intervention: metamizole drops 50%
Number of subjects: 60
Study 30950919 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL)
Number of subjects: 338
Study 30950919 — intervention group
Group type: COMPARATOR
Intervention: Traditional Lecture-Based Approach
Number of subjects: 338
Study 30399477 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate volume aerobic exercise (MA)
Number of subjects: 5
Study 30399477 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume aerobic exercise (HA)
Number of subjects: 5
Study 30399477 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 5
Study 30399477 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate volume resistance exercise (MR)
Number of subjects: 5
Study 8023772 — intervention group
Group type: EXPERIMENTAL
Intervention: < 60% diameter stenosis in the infarct-related artery
Number of subjects: 1752
Study 8023772 — intervention group
Group type: COMPARATOR
Intervention: > or = 60% diameter stenosis with TIMI grade 2 or 3 flow
Number of subjects: 1752
Study 8023772 — intervention group
Group type: COMPARATOR
Intervention: Total occlusion (TIMI grade 0 or 1 flow)
Number of subjects: 1752
Study 24887796 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (resection with or without plate fixation)
Number of subjects: 24
Study 21490622 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful anti-hypertensive treatment
Number of subjects: 41
Study 21490622 — intervention group
Group type: COMPARATOR
Intervention: Normotensive individuals (control group)
Number of subjects: 41
Study 20954414 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy and kinesy-therapy
Number of subjects: 45
Study 20954414 — intervention group
Group type: COMPARATOR
Intervention: Interferential current and kinesy-therapy
Number of subjects: 45
Study 18296423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone 6 mg/m(2)/day x 5 days every 21 days (arm A)
Number of subjects: 85
Study 18296423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone 20 mg/m(2) on days 1, 8, and 15 of a 28-day cycle (arm B)
Number of subjects: 85
Study 18296423 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (taxane-naive and taxane-exposed)
Number of subjects: 85
Study 18296423 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B (taxane-naive and taxane-exposed)
Number of subjects: 85
Study 18296423 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly ixabepilone 20 mg/m(2)
Number of subjects: 85
Study 18296423 — intervention group
Group type: EXPERIMENTAL
Intervention: Common grades 3 and 4 toxic effects
Number of subjects: 85
Study 16393729 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine challenge
Number of subjects: 42
Study 16393729 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine challenge
Number of subjects: 42
Study 16393729 — intervention group
Group type: COMPARATOR
Intervention: Control (saline challenge)
Number of subjects: 42
Study 14765564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment system
Number of subjects: 413
Study 10665721 — intervention group
Group type: EXPERIMENTAL
Intervention: SHP (Scientific Hip Prosthesis)
Number of subjects: 40
Study 10665721 — intervention group
Group type: COMPARATOR
Intervention: Lubinus SP2 prosthesis
Number of subjects: 40
Study 10665721 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 8886909 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (2000 mg 2‐3 hours before cisplatin)
Number of subjects: 14
Study 8886909 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (first course without methylprednisolone)
Number of subjects: 14
Study 1303780 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporin A, daily dose of 100 mg for 2 years
Number of subjects: 30
Study 1303780 — intervention group
Group type: COMPARATOR
Intervention: not given cyclosporin
Number of subjects: 30
Study 3000139 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4-9 analogue (Org 2766)
Number of subjects: 49
Study 3000139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 30952941 — intervention group
Group type: EXPERIMENTAL
Intervention: ranolazine
Number of subjects: 20
Study 30952941 — intervention group
Group type: COMPARATOR
Intervention: standard treatment
Number of subjects: 20
Study 30170580 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular repair
Number of subjects: 259
Study 30170580 — intervention group
Group type: COMPARATOR
Intervention: Capsular resection
Number of subjects: 259
Study 26817624 — intervention group
Group type: EXPERIMENTAL
Intervention: IV iron
Number of subjects: 72
Study 26817624 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 72
Study 24694205 — intervention group
Group type: EXPERIMENTAL
Intervention: Low vitamin B12 group (B12 < 221 pmol/l)
Number of subjects: 53
Study 24694205 — intervention group
Group type: COMPARATOR
Intervention: Normal vitamin B12 group
Number of subjects: 53
Study 22566538 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron plus folic acid (12.5 mg of iron and 50 μg of folic acid)
Number of subjects: 734
Study 22566538 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (10 mg)
Number of subjects: 734
Study 22566538 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron plus folic acid and zinc
Number of subjects: 734
Study 22566538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734
Study 20479662 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Number of subjects: 96
Study 20479662 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane/fentanyl anesthesia
Number of subjects: 96
Study 18565127 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500 or 2550 mg/day for 8 months
Number of subjects: 82
Study 16004610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure
Number of subjects: 41
Study 16004610 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS stimulation
Number of subjects: 41
Study 16004610 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-smokers
Number of subjects: 41
Study 12088463 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive range of motion (PROM) exercises during phase A for group 1 (3 participants)
Number of subjects: 6
Study 12088463 — intervention group
Group type: COMPARATOR
Intervention: Passive range of motion (PROM) exercises during phase B for group 2 (3 participants)
Number of subjects: 6
Study 10609921 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb as an adjunct to standard therapy
Number of subjects: 112
Study 7572107 — intervention group
Group type: EXPERIMENTAL
Intervention: Early menarche
Number of subjects: 3743
Study 7572107 — intervention group
Group type: EXPERIMENTAL
Intervention: Late menarche
Number of subjects: 3743
Study 7572107 — intervention group
Group type: EXPERIMENTAL
Intervention: Menarcheal age
Number of subjects: 3743
Study 1657502 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin inhalation at 50 litres/min
Number of subjects: 12
Study 1657502 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin inhalation at 100 litres/min
Number of subjects: 12
Study 1657502 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid inhalation at 50 litres/min
Number of subjects: 12
Study 6355047 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir low dose (5 mg/kg every 8 h)
Number of subjects: 0
Study 6355047 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir high dose (500 mg/m2 every 8 h)
Number of subjects: 0
Study 6355047 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 31665746 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient treatment (up to 12 capsules/day)
Number of subjects: 107
Study 31665746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 29793736 — intervention group
Group type: EXPERIMENTAL
Intervention: High dependence smokers (TTFC ≤ 5 min after waking)
Number of subjects: 0
Study 29793736 — intervention group
Group type: COMPARATOR
Intervention: Low dependence smokers (TTFC > 60 min after waking)
Number of subjects: 0
Study 27582622 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) of active MTrPs in the trapezius muscle plus passive stretch
Number of subjects: 44
Study 27582622 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - passive stretch of the trapezius muscle only
Number of subjects: 44
Study 27582622 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN)
Number of subjects: 44
Study 24768410 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT+CM
Number of subjects: 92
Study 22583708 — intervention group
Group type: EXPERIMENTAL
Intervention: Family psychoeducation (four 2-hour multiple-family sessions)
Number of subjects: 57
Study 22583708 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 57
Study 20176350 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 395
Study 20176350 — intervention group
Group type: COMPARATOR
Intervention: White light (WL)
Number of subjects: 395
Study 18023788 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing (no specific intervention)
Number of subjects: 1222
Study 18023788 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics of adolescents who received HIV testing
Number of subjects: 1222
Study 16220331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (60-min infusion)
Number of subjects: 13
Study 12103471 — intervention group
Group type: EXPERIMENTAL
Intervention: Dawn simulation (250 lux)
Number of subjects: 50
Study 12103471 — intervention group
Group type: COMPARATOR
Intervention: Dim placebo signal (0.2‐2 lux)
Number of subjects: 50
Study 10450009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral catheterization with patient mobilization (standing upright and walking 5 meters)
Number of subjects: 26
Study 10450009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral catheterization with patient mobilization (supine after walking 5 meters)
Number of subjects: 26
Study 10450009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral catheterization (all phases of maneuvers)
Number of subjects: 26
Study 8528821 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient, once a week group treatment for sexually abused girls
Number of subjects: 30
Study 8528821 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 30
Study 2222351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal histamine (maximum nasal dose of 250 micrograms)
Number of subjects: 22
Study 2222351 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 22
Study 7010527 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone sodium
Number of subjects: 0
Study 7010527 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 0
Study 31910803 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based computerized executive function training programme (12 weeks, 5 days a week, 30 min a day training, total dose = 30 h)
Number of subjects: 60
Study 31910803 — intervention group
Group type: COMPARATOR
Intervention: Usual care (waitlist group)
Number of subjects: 60
Study 31131928 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin combined with dapoxetine
Number of subjects: 251
Study 31131928 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 251
Study 26488362 — intervention group
Group type: EXPERIMENTAL
Intervention: PFNA
Number of subjects: 90
Study 26488362 — intervention group
Group type: EXPERIMENTAL
Intervention: PFLCP
Number of subjects: 90
Study 26488362 — intervention group
Group type: COMPARATOR
Intervention: DHS
Number of subjects: 90
Study 25736623 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 270
Study 25736623 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 270
Study 25736623 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 270
Study 23461009 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin 1.5% infusion
Number of subjects: 136
Study 23461009 — intervention group
Group type: COMPARATOR
Intervention: Official therapy
Number of subjects: 136
Study 21204695 — intervention group
Group type: EXPERIMENTAL
Intervention: High-immediacy level exposure on the PHR Web site
Number of subjects: 252
Study 21204695 — intervention group
Group type: COMPARATOR
Intervention: Control for privacy self-efficacy beliefs
Number of subjects: 252
Study 18703544 — intervention group
Group type: EXPERIMENTAL
Intervention: Heidelberg Parent-based Language Intervention (HPLI), 3-month duration
Number of subjects: 61
Study 18703544 — intervention group
Group type: COMPARATOR
Intervention: Waiting group (control), 12-month waiting period
Number of subjects: 61
Study 18703544 — intervention group
Group type: EXPERIMENTAL
Intervention: Heidelberg Parent-based Language Intervention (HPLI)
Number of subjects: 61